Women were less than half of the people tested for almost all of these common medicines.

High blood pressure

amlodipine

Dozens of side effects are reported more often by women, but women were under 45% of the people in its studies.

  • 44.3%

    of the people in the studies were women

  • 55%

    of studies did not allow pregnant women

  • 3%

    looked at results for women separately

Was someone like me tested?

Choose the group that fits you.

Not one of these studies reported results separately for any of the groups below.

Barely studied

Pregnant women

55% of studies would not let pregnant women join. Only 2 small studies (191 women in all) looked at pregnancy or just after birth.

What do we know?

What the FDA drug label says

There is too little information to know if it causes birth defects or miscarriage.

Studies focused on this group (2)

Good to know

Ankle and leg swelling is a common side effect and happens more often in women.

What women report more

Compared with men taking the same medicine.

  • 2.1×Changes to the front of the eye
  • 2.0×Nerve-coating damage (like MS-type symptoms)
  • 1.9×Broken bones
  • 1.8×Ear problems

How many times more often women reported each problem than men taking the same medicine, based on reports to the FDA. This is a warning sign, not proof the medicine caused it.

Make it about you

Check it against your medicines

Check amlodipine against the medicines, pregnancy and birth control in your profile.

Join to check

Women's experiences

Join or sign in to share, like or save. You'll fill in a short health profile so your story has context and we can check your medicines.

No one has shared yet. Your story could help the next woman.

All the details

Every number behind this page.

Who was in the studies

85,533 people in 133 studies

37,895 womenmiddle line = equal numbers47,638 men

Race

  • White72.9%
  • Black / African American17.8%
  • Asian4.3%
  • More than one race0.3%
  • Other0.2%

Studies didn't say how many of the women were Black, Asian or another race — only totals for everyone.

Hispanic or Latina
10.7%
Age 65 or older
43%
Studies with men only
5
Studies with women only
4
Rules that kept women out

Share of studies with each rule.

  • 59%

    No heart disease

    Women with heart disease, heart rhythm problems or a past heart attack were turned away.

    See the exact rule
    “Subjects having a history of the following within the last six months: myocardial infarction (MI), unstable angina pectoris, percutaneous coronary intervention, heart failure, hypertensive encephalopathy, cerebrovascular accident (stroke),…” NCT00923091
  • 55%

    No pregnant women

    Women who were pregnant could not join.

    See the exact rule
    “Women who are pregnant or of child-bearing potential” NCT02068495
  • 35%

    No breastfeeding moms

    Women who were breastfeeding could not join.

    See the exact rule
    “Female subjects of childbearing potential who are pregnant or lactating.” NCT00923091
  • 34%

    No diabetes

    Women with diabetes were turned away.

    See the exact rule
    “Subjects with uncontrolled Type 1 or Type 2 diabetes defined as HbA1c \> 9.0%. Diabetics must have documentation of HbA1c within 6 months of the Screening Visit, or must have their HbA1c assessed prior to randomisation. Note: subjects with…” NCT00923091
  • 28%

    No cancer

    Women with current or past cancer were turned away.

    See the exact rule
    “Subjects with a history of a wasting disease (e.g. cancer), autoimmune diseases, connective tissue diseases, major allergies or angioneurotic oedema.” NCT00923091
  • 26%

    Had to use birth control

    Women who couldn't or didn't want to use birth control were turned away.

    See the exact rule
    “Will practice birth control throughout the study by the following: oral or patch contraceptive, injectable or implantable contraceptive medication, intrauterine device, diaphragm or female condom plus spermicide” NCT00649389
What nobody checked

Share of studies that recorded each thing.

  • 3%
    Results shown separately for women
  • 0%
    Whether anyone was pregnant
  • 0%
    Whether women were past menopause
  • 13%
    Body weight (BMI)
  • 12%
    Hispanic / Latina or not
  • 28%
    Race
All 136 studies

Study titles and rules are shown in their original English.

StudyPhasepeople% women
Amlodipine 10mg Drug Use Investigation
NCT01252563
—13,34343.8%
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
NCT00000620
310,25138.6%
Candesartan Cilexetil/Amlodipine Besilate Combination Tablets LD, HD Special Drug Use Surveillance "Hypertension: Long-Term Use"
NCT02068495
—3,30051.3%
Parallel-Group Comparison of Olmesartan (OLM), Amlodipine (AML) and Hydrochlorothiazid (HCTZ) in Hypertension
NCT00923091
32,68953.7%
Safety and Efficacy Study of a Triple Combination Therapy in Subjects With Hypertension
NCT00649389
32,49247.1%
Twynsta Study With Lifestyle Modifications in Korean Patients With Hypertension
NCT01316419
—1,82442.7%
Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension
NCT00739973
31,68849.2%
Valsartan Intensified Primary Care Reduction of Blood Pressure Study
NCT00902304
41,56238.3%
Efficacy and Safety of Valsartan and Amlodipine in Patients With Essential Hypertension
NCT00425373
2/31,46827.6%
Caduet vs Usual Care in Subjects With Hypertension and Additional Risk Factors
NCT00407537
41,46148%
Telmisartan (Micardis) and Amlodipine (Norvasc) - Factorial Design Study for the Treatment of Hypertension
NCT00281580
31,46149.6%
Efficacy and Safety of GMRx2 Compared to Dual Combinations for the Treatment of Hypertension
NCT04518293
31,38551.4%
Aliskiren and the Calcium Channel Blocker Amlodipine Combination as an Initial Treatment Strategy for Hypertension
NCT00797862
31,25449.4%
Amlodipine/Atorvastatin (Caduet®) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)
NCT01107743
—1,24563.2%
Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension
NCT00765674
31,19139.5%
Efficacy and Safety of Valsartan/Amlodipine Compared to Amlodipine in Patients With Essential Hypertension
NCT00437645
31,18348.1%
The Use of TrIple Fixed-dose Combination in the Treatment of Arterial Hypertension
NCT03722524
—1,14860.4%
Telmisartan/Amlodipine (80/5) vs. Telmisartan/Amlodipine (40/5) vs. Amlodipine 10 or 5 in Resistant Hypertension
NCT00558428
31,09737.8%
Azilsartan/Amlodipine Combination Tablets LD & HD Specified Drug-use Survey "Long-term Use Survey"
NCT02181816
—1,03146.8%
A Dose Escalation Study of a Combination Antihypertensive Drug in the Treatment of Various Groups of Patients Who do Not Respond to Single Drug Treatment of Their High Blood Pressure
NCT00791258
499949.1%
Open Label Study Telmisartan and Amlodipine in Hypertension
NCT00614380
397637.4%
Telmisartan/Amlodipine (80/10) vs. Telmisartan/Amlodipine (40/10) vs. amlodipine10 in Resistant Hypertension
NCT00553267
394744.2%
Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension
NCT01237223
394430.5%
Efficacy/Safety of Valsartan Plus Amlodipine and Valsartan Alone in Patients With Hypertension
NCT00413413
391637.8%
A Safety and Efficacy Trial of Aliskiren 150mg , 300 mg Compared to Ramipril 5mg, 10mg in the Elderly
NCT00368277
390152.4%
Aliskiren HCTZ Compared to Amlodipine in Patients With Stage 2 Systolic Hypertension and Diabetes Mellitus
NCT00787605
486049%
Telmisartan and Amlodipine Fixed Dose Combination [FDC] Trial for the Treatment of Severe Hypertension
NCT00860262
385848.1%
Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients With Hypertension Not Adequately Responding to Amlodipine Alone
NCT00778921
384738.7%
26-week Open Study of telmisartan40mg+amlodipine10mg or telmisartan80mg+amlodipine10 mg in Hypertension
NCT00624052
383843.8%
Perindopril Amlodipine for the Treatment of Hypertension
NCT01556997
383748.6%
Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients Not Adequately Responding to Aliskiren Alone
NCT00777946
382039.5%
Safety, Tolerability, and Efficacy of Once Daily Amlodipine/Valsartan 5/80 as Compared to Amlodipine/Valsartan 5/40 or to Amlodipine 5 mg Monotherapy in Patients 65 Years of Age and Older With Essential Hypertension
NCT00699192
381952.7%
Hydrochlorothiazide as add-on to Olmesartan/Amlodipine in Hypertension
NCT00902538
380842%
The Effects of Moderate vs. Aggressive Treatment With Valsartan + Amlodipine on Patients With Hypertension Uncontrolled by Angiotensin-Receptor Blocker (Herein, ARB) Monotherapy
NCT00666536
472343.4%
Azilsartan Circadian and Sleep Pressure
NCT01762501
—71843.7%
Telmisartan Fixed Dose Combination vs Amlodipine in Hypertensive Patients With Type 2 Diabetes Mellitus
NCT00877929
370648.3%
Efficacy/Safety of Valsartan Plus Amlodipine and Amlodipine Alone in Patients With Hypertension
NCT00413049
369634.9%
Olmesartan and an add-on Treatment in Patients With Mild to Moderate Hypertension
NCT00311155
469448.6%
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)
NCT05103332
265842.9%
Efficacy and Safety of Valsartan/Amlodipine in Patients With Mild to Moderate Essential Hypertension
NCT01001572
365144.7%